USPTO serial 79406165
BICYCLE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 27, 2026
- Examiner
- BERGER, MAGDALENA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BICYCLE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CHRISTINA M. LICURSI
CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products, namely, pharmaceutical preparations for use in oncology for both solid and liquid tumours, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for use as diagnostics, namely, diagnostic preparations for medical use; pharmaceutical preparations for use as clinical imaging agents for positron emission tomography use | ACTIVE | — |
| 042 | Scientific research; scientific study and research in the field of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; laboratory research services in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; providing information, consultancy and advisory services relating to the design, planning and implementation of scientific and clinical research for others | ACTIVE | — |
| 044 | Medical services; medical testing for diagnostic or treatment purposes; healthcare services; pharmaceutical services, namely, pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals, namely, pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in connection with respiratory disease; medical services in connection with cardiovascular disease; medical services in connection with metabolic disease; medical services in connection with the treatment and/or prevention of viral infections; medical services in connection with diagnostics and imaging; medical services in connection with renal disease; medical services in connection with gastrointestinal disease; medical services in connection with muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bicycletx Limited
- Other trademarks owned by Bicycletx Limited
- Other trademarks owned by Bicycletx Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named BICYCLE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 20, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 3, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Aug 3, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 27, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 26, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Mar 9, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Mar 9, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 27, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jan 27, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 2, 2026 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Jan 2, 2026 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jan 2, 2026 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Aug 8, 2025 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jul 21, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jul 21, 2025 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jul 17, 2025 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| Jul 17, 2025 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Apr 14, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Mar 26, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 26, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 26, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 26, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 26, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 26, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 18, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 18, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 12, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 25, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 21, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 21, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 21, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 29, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 10, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 10, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 26, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 25, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 16, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 15, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 15, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 15, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Oct 10, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |